Polyarteritis nodosa epidemiology and demographics
Polyarteritis nodosa Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polyarteritis nodosa epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Polyarteritis nodosa epidemiology and demographics |
Polyarteritis nodosa epidemiology and demographics in the news |
Risk calculators and risk factors for Polyarteritis nodosa epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]
Overview
Epidemiology and Demographics
Incidence
Prevalence
- The prevalence among alaskan population suffering with hepatitis B infection is approximately 7.7 per 100,000 individuals.
Age
- Patients of all age groups may develop PAN.
- PAN is mostly diagnosed in patients aged 45-65 years. [2]
Race
- There is no racial predilection to PAN.
Gender
- Males are more commonly affected by PAN than females. The male to female ratio is approximately 1.5 to 1.
Region
- Population prevalence estimates for polyarteritis nodosa (PAN) range from 2 to 33 per million across the European Countries [3]
- The annual incidence in three regions of Europe was estimated to be 4.4 to 9.7 per million [4].
References
- ↑ McMahon BJ, Heyward WL, Templin DW, Clement D, Lanier AP (January 1989). "Hepatitis B-associated polyarteritis nodosa in Alaskan Eskimos: clinical and epidemiologic features and long-term follow-up". Hepatology. 9 (1): 97–101. PMID 2562798.
- ↑ Colmegna I, Maldonado-Cocco JA (August 2005). "Polyarteritis nodosa revisited". Curr Rheumatol Rep. 7 (4): 288–96. PMID 16045832.
- ↑ Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden". Rheumatology (Oxford). 46 (8): 1329–37. doi:10.1093/rheumatology/kem107. PMID 17553910.
- ↑ Watts RA, Lane SE, Bentham G, Scott DG (2000). "Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom". Arthritis Rheum. 43 (2): 414–9. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. PMID 10693883.